J. Ferlay, E. Steliarova-foucher, and J. Lortet-tieulent, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-403, 1990.
DOI : 10.1016/j.ejca.2012.12.027

J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-386, 2015.
DOI : 10.1016/S1470-2045(12)70137-7

S. Neupane, F. Bray, and A. Auvinen, National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis, World Journal of Urology, vol.384, issue.6, pp.851-859, 2017.
DOI : 10.1016/S0140-6736(14)60525-0

D. Parkin and F. Bray, International Patterns of Cancer Incidence and Mortality, Cancer Epidemiol Prev, pp.101-138, 2006.
DOI : 10.1093/acprof:oso/9780195149616.003.0008

N. Sharifi, The 5?-androstanedione pathway to dihydrotestosterone in castrationresistant prostate cancer, J Investig Med Off Publ Am Fed Clin Res, vol.60, issue.2, pp.504-511, 2012.

E. Mostaghel and P. Nelson, Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications, Best Practice & Research Clinical Endocrinology & Metabolism, vol.22, issue.2, pp.243-58, 2008.
DOI : 10.1016/j.beem.2008.01.003

M. Cutress, H. Whitaker, I. Mills, M. Stewart, and D. Neal, Structural basis for the nuclear import of the human androgen receptor, Journal of Cell Science, vol.121, issue.7, pp.957-68, 2008.
DOI : 10.1242/jcs.022103

L. Gaughan, I. Logan, S. Cook, D. Neal, and C. Robson, Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor, Journal of Biological Chemistry, vol.17, issue.29, pp.25904-25917, 2002.
DOI : 10.1074/jbc.C000909200

M. Fu, M. Rao, and C. Wang, Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth, Molecular and Cellular Biology, vol.23, issue.23, pp.8563-75, 2003.
DOI : 10.1128/MCB.23.23.8563-8575.2003

M. Fu, C. Wang, and J. Wang, Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans-Repression Function, Molecular and Cellular Biology, vol.22, issue.10, pp.3373-88, 2002.
DOI : 10.1128/MCB.22.10.3373-3388.2002

M. Fu, C. Wang, and A. Reutens, p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation, Journal of Biological Chemistry, vol.19, issue.27, pp.20853-60, 2000.
DOI : 10.1128/MCB.19.5.3474

P. Matias, P. Donner, and R. Coelho, Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor, Journal of Biological Chemistry, vol.31, issue.34, pp.26164-71, 2000.
DOI : 10.1107/S0108767386099622

J. Sack, K. Kish, and C. Wang, Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone, Proceedings of the National Academy of Sciences, vol.11, issue.2, pp.4904-4913, 2001.
DOI : 10.1016/0263-7855(93)87009-T

B. He, R. Gampe, and A. Kole, Structural Basis for Androgen Receptor Interdomain and Coactivator Interactions Suggests a Transition in Nuclear Receptor Activation Function Dominance, Molecular Cell, vol.16, issue.3, pp.425-463, 2004.
DOI : 10.1016/j.molcel.2004.09.036

M. Van-royen, S. Cunha, and M. Brink, Compartmentalization of androgen receptor protein???protein interactions in living cells, The Journal of Cell Biology, vol.108, issue.1, pp.63-72, 2007.
DOI : 10.1083/jcb.122.2.283

Y. Shang, M. Myers, and M. Brown, Formation of the Androgen Receptor Transcription Complex, Molecular Cell, vol.9, issue.3, pp.601-611, 2002.
DOI : 10.1016/S1097-2765(02)00471-9

S. Stelloo, E. Nevedomskaya, and H. Van-der-poel, Androgen receptor profiling predicts prostate cancer outcome, EMBO Molecular Medicine, vol.7, issue.11, pp.1450-64, 2015.
DOI : 10.15252/emmm.201505424

M. Zhu, J. Partin, E. Bruckheimer, S. Strup, and N. Kyprianou, TGF-?? signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells, The Prostate, vol.59, issue.3, pp.287-95, 2008.
DOI : 10.1016/S1476-5586(03)80058-1

Z. Ding, C. Wu, and G. Chu, SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression, Nature, vol.102, issue.7333, pp.269-73, 2011.
DOI : 10.1073/pnas.0506580102

L. Antony, F. Van-der-schoor, S. Dalrymple, and J. Isaacs, transcription, The Prostate, vol.72, issue.11, pp.1118-1149, 2014.
DOI : 10.1002/pros.22504

C. Barbieri, S. Baca, and M. Lawrence, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nature Genetics, vol.12, issue.6, pp.685-694, 2012.
DOI : 10.1593/neo.10726

S. Baca, D. Prandi, and M. Lawrence, Punctuated Evolution of Prostate Cancer Genomes, Cell, vol.153, issue.3, pp.666-77, 2013.
DOI : 10.1016/j.cell.2013.03.021

C. Cooper, R. Eeles, and D. Wedge, Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue, Nature Genetics, vol.486, issue.4, pp.367-72, 2015.
DOI : 10.1093/nar/gkm383

S. Tomlins, D. Rhodes, and S. Perner, Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer, Science, vol.310, issue.5748, pp.644-652, 2005.
DOI : 10.1126/science.1117679

C. Huggins and C. Hodges, Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate, CA: A Cancer Journal for Clinicians, vol.22, issue.4, pp.232-272, 1972.
DOI : 10.3322/canjclin.22.4.232

G. Tolis, D. Ackman, and A. Stellos, Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists., Proceedings of the National Academy of Sciences, vol.79, issue.5, pp.1658-62, 1982.
DOI : 10.1073/pnas.79.5.1658

N. Mottet, J. Bellmunt, and M. Bolla, EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, European Urology, vol.59, issue.4, pp.572-83, 2011.
DOI : 10.1016/j.eururo.2011.01.025

S. Mohile, K. Mustian, K. Bylow, W. Hall, and W. Dale, Management of complications of androgen deprivation therapy in the older man, Critical Reviews in Oncology/Hematology, vol.70, issue.3, pp.235-55, 2009.
DOI : 10.1016/j.critrevonc.2008.09.004

L. Taylor, S. Canfield, and X. Du, Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer, Cancer, vol.299, issue.11, pp.2388-99, 2009.
DOI : 10.3816/CGC.2005.n.009

M. Grossmann and J. Zajac, Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?, Clinical Endocrinology, vol.294, issue.3, pp.289-93, 2011.
DOI : 10.1001/jama.294.2.238

B. Ehdaie, C. Atoria, and A. Gupta, Androgen deprivation and thromboembolic events in men with prostate cancer, Cancer, vol.112, issue.8 suppl, pp.3397-406, 2012.
DOI : 10.1002/cncr.23421

B. Hellerstedt and K. Pienta, The Current State of Hormonal Therapy for Prostate Cancer, CA: A Cancer Journal for Clinicians, vol.52, issue.3, pp.154-79, 2002.
DOI : 10.3322/canjclin.52.3.154

N. Sharifi, J. Gulley, and W. Dahut, Androgen Deprivation Therapy for Prostate Cancer, JAMA, vol.294, issue.2, pp.238-282, 2005.
DOI : 10.1001/jama.294.2.238

D. Loblaw, K. Virgo, and R. Nam, Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline, Journal of Clinical Oncology, vol.25, issue.12, pp.1596-605, 2007.
DOI : 10.1200/JCO.2006.10.1949

D. Amico, A. Manola, J. Loffredo, M. Renshaw, A. Dellacroce et al., 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer, JAMA, vol.292, issue.7, pp.821-828, 2004.
DOI : 10.1001/jama.292.7.821

M. Bolla, T. De-reijke, and G. Van-tienhoven, Duration of Androgen Suppression in the Treatment of Prostate Cancer, New England Journal of Medicine, vol.360, issue.24, pp.2516-2543, 2009.
DOI : 10.1056/NEJMoa0810095

URL : https://hal.archives-ouvertes.fr/hal-00492521

L. Klotz, L. Boccon-gibod, and N. Shore, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, BJU International, vol.49, issue.Suppl. 1, pp.1531-1539, 2008.
DOI : 10.1111/j.1464-410X.2008.08183.x

M. Bolla, L. Collette, and L. Blank, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, The Lancet, vol.360, issue.9327, pp.103-109, 2002.
DOI : 10.1016/S0140-6736(02)09408-4

C. Labrie, L. Cusan, M. Plante, S. Lapointe, and F. Labrie, Analysis of the androgenic activity of synthetic ???progestins??? currently used for the treatment of prostate cancer, Journal of Steroid Biochemistry, vol.28, issue.4, pp.379-84, 1987.
DOI : 10.1016/0022-4731(87)91054-5

Y. Chen, N. Clegg, and H. Scher, Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target, The Lancet Oncology, vol.10, issue.10, pp.981-91, 2009.
DOI : 10.1016/S1470-2045(09)70229-3

P. Iversen, C. Tyrrell, and A. Kaisary, BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP, The Journal of Urology, vol.164, issue.5, pp.1579-82, 2000.
DOI : 10.1016/S0022-5347(05)67032-2

G. Bales and G. Chodak, A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer, Urology, vol.47, issue.1, pp.38-43, 1996.
DOI : 10.1016/S0090-4295(96)80007-0

C. Tyrrell, A. Kaisary, and P. Iversen, A Randomised Comparison of &lsquo;Casodex&rsquo;<sup>TM</sup> (Bicalutamide) 150&nbsp;mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer, European Urology, vol.33, issue.5, pp.447-56, 1998.
DOI : 10.1159/000019634

E. Crawford, M. Eisenberger, and D. Mcleod, A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma, New England Journal of Medicine, vol.321, issue.7, pp.419-443, 1989.
DOI : 10.1056/NEJM198908173210702

M. Eisenberger, B. Blumenstein, and E. Crawford, Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer, New England Journal of Medicine, vol.339, issue.15, pp.1036-1078, 1998.
DOI : 10.1056/NEJM199810083391504

G. Dijkman, R. Janknegt, D. Reijke, T. Debruyne, and F. , Long-Term Efficacy and Safety of Nilutamide Plus Castration in Advanced Prostate Cancer, and the Significance of Early Prostate Specific Antigen Normalization, The Journal of Urology, vol.158, issue.1, pp.160-163, 1997.
DOI : 10.1097/00005392-199707000-00051

A. Horwich, J. Hugosson, and T. De-reijke, Prostate cancer: ESMO Consensus Conference Guidelines 2012, Annals of Oncology, vol.27, issue.10, pp.1141-62, 2013.
DOI : 10.1200/JCO.2008.19.2146

URL : https://academic.oup.com/annonc/article-pdf/24/5/1141/571331/mds624.pdf

J. Mohler, P. Kantoff, and A. Armstrong, Prostate Cancer, Version 2.2014, Journal of the National Comprehensive Cancer Network, vol.12, issue.5, pp.686-718, 2014.
DOI : 10.6004/jnccn.2014.0072

A. Stephenson, P. Scardino, and J. Eastham, Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy, Journal of Clinical Oncology, vol.23, issue.28, pp.7005-7017, 2005.
DOI : 10.1200/JCO.2005.01.867

M. Bolla, G. Van-tienhoven, and P. Warde, External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, The Lancet Oncology, vol.11, issue.11, pp.1066-73, 2010.
DOI : 10.1016/S1470-2045(10)70223-0

M. Pilepich, K. Winter, and C. Lawton, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma???long-term results of phase III RTOG 85???31, International Journal of Radiation Oncology*Biology*Physics, vol.61, issue.5, pp.1285-90, 2005.
DOI : 10.1016/j.ijrobp.2004.08.047

E. Horwitz, K. Bae, and G. Hanks, Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer, Journal of Clinical Oncology, vol.26, issue.15, pp.2497-504, 2008.
DOI : 10.1200/JCO.2007.14.9021

A. Widmark, O. Klepp, and A. Solberg, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, The Lancet, vol.373, issue.9660, pp.301-309, 2009.
DOI : 10.1016/S0140-6736(08)61815-2

M. Mason, W. Parulekar, and M. Sydes, Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer, Journal of Clinical Oncology, vol.33, issue.19, pp.2143-50, 2015.
DOI : 10.1200/JCO.2014.57.7510

K. Fizazi, L. Faivre, and F. Lesaunier, Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial, The Lancet Oncology, vol.16, issue.7, pp.787-94, 2015.
DOI : 10.1016/S1470-2045(15)00011-X

A. Ross, K. Yousefi, and E. Davicioni, Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men, European Urology, vol.69, issue.3, pp.496-504, 2016.
DOI : 10.1016/j.eururo.2015.04.016

S. Eggener, P. Scardino, and P. Walsh, Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy, The Journal of Urology, vol.185, issue.3, pp.869-75, 2011.
DOI : 10.1016/j.juro.2010.10.057

P. Carroll, J. Parsons, and G. Andriole, NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016, Journal of the National Comprehensive Cancer Network, vol.14, issue.5, pp.509-528, 2016.
DOI : 10.6004/jnccn.2016.0060

N. Erho, A. Crisan, and I. Vergara, Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy, PLoS ONE, vol.18, issue.6, p.66855, 2013.
DOI : 10.1371/journal.pone.0066855.s005

R. Karnes, E. Bergstralh, and E. Davicioni, Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population, The Journal of Urology, vol.190, issue.6, pp.2047-53, 2013.
DOI : 10.1016/j.juro.2013.06.017

R. Den, F. Feng, and T. Showalter, Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy, International Journal of Radiation Oncology*Biology*Physics, vol.89, issue.5
DOI : 10.1016/j.ijrobp.2014.04.052

E. Klein, K. Yousefi, and Z. Haddad, A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy, European Urology, vol.67, issue.4, pp.778-86, 2015.
DOI : 10.1016/j.eururo.2014.10.036

A. Ross, M. Johnson, and K. Yousefi, Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men, European Urology, vol.69, issue.1, pp.157-65, 2016.
DOI : 10.1016/j.eururo.2015.05.042

D. Spratt, K. Yousefi, and S. Deheshi, Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease, Journal of Clinical Oncology, vol.35, issue.18, pp.1991-1999, 2017.
DOI : 10.1200/JCO.2016.70.2811

C. Pound, A. Partin, M. Eisenberger, D. Chan, J. Pearson et al., Natural History of Progression After PSA Elevation Following Radical Prostatectomy, JAMA, vol.281, issue.17, pp.1591-1598, 1999.
DOI : 10.1001/jama.281.17.1591

D. Amico, A. Moul, J. Carroll, P. Sun, L. Lubeck et al., Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy, JNCI Journal of the National Cancer Institute, vol.54, issue.3, pp.1376-83, 2003.
DOI : 10.2307/2533853

J. Ward, M. Blute, J. Slezak, E. Bergstralh, and H. Zincke, The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy, The Journal of Urology, vol.170, issue.5, pp.1872-1878, 2003.
DOI : 10.1097/01.ju.0000091876.13656.2e

O. Okotie, W. Aronson, and J. Wieder, PREDICTORS OF METASTATIC DISEASE IN MEN WITH BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMY, The Journal of Urology, vol.171, issue.6, pp.2260-2264, 2004.
DOI : 10.1097/01.ju.0000127734.01845.99

S. Freedland, E. Humphreys, and L. Mangold, Risk of Prostate Cancer???Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy, JAMA, vol.294, issue.4, pp.433-442, 2005.
DOI : 10.1001/jama.294.4.433

S. Boorjian, R. Karnes, P. Crispen, L. Rangel, E. Bergstralh et al., Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and Survival, The Journal of Urology, vol.182, issue.6, pp.2708-2722, 2009.
DOI : 10.1016/j.juro.2009.08.027

C. Carrie, A. Hasbini, and G. De-laroche, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial, The Lancet Oncology, vol.17, issue.6, pp.747-56, 2016.
DOI : 10.1016/S1470-2045(16)00111-X

N. Bruchovsky, P. Rennie, A. Coldman, S. Goldenberg, M. To et al., Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma, Cancer Res, vol.50, issue.8, pp.2275-82, 1990.

K. Akakura, N. Bruchovsky, S. Goldenberg, P. Rennie, A. Buckley et al., Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen, Cancer, vol.49, issue.9, pp.2782-90, 1993.
DOI : 10.1042/bj1270561

N. Sato, M. Gleave, and N. Bruchovsky, Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model, The Journal of Steroid Biochemistry and Molecular Biology, vol.58, issue.2, pp.139-185, 1996.
DOI : 10.1016/0960-0760(96)00018-0

J. Crook, O. Callaghan, C. Duncan, and G. , Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy, New England Journal of Medicine, vol.367, issue.10, pp.895-903, 2012.
DOI : 10.1056/NEJMoa1201546

I. Tannock, R. De-wit, and W. Berry, Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, New England Journal of Medicine, vol.351, issue.15, pp.1502-1514, 2004.
DOI : 10.1056/NEJMoa040720

D. Petrylak, C. Tangen, and M. Hussain, Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer, New England Journal of Medicine, vol.351, issue.15, pp.1513-1533, 2004.
DOI : 10.1056/NEJMoa041318

G. Oades, J. Coxon, and K. Colston, The potential role of bisphosphonates in prostate cancer, Prostate Cancer and Prostatic Diseases, vol.289, issue.Suppl 7, pp.264-72, 2002.
DOI : 10.1126/science.289.5484.1508

F. Saad, D. Gleason, and R. Murray, A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma, JNCI Journal of the National Cancer Institute, vol.14, issue.3, pp.1458-68, 2002.
DOI : 10.2165/00002018-199614030-00003

D. Dearnaley, M. Sydes, and M. Mason, A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial), CancerSpectrum Knowledge Environment, vol.95, issue.17, pp.1300-1311, 2003.
DOI : 10.1093/jnci/djg038

W. Berry, S. Dakhil, M. Modiano, M. Gregurich, and L. Asmar, Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer, The Journal of Urology, vol.168, issue.6, pp.2439-2482, 2002.
DOI : 10.1016/S0022-5347(05)64163-8

P. Kantoff, S. Halabi, and M. Conaway, Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study, Journal of Clinical Oncology, vol.17, issue.8, pp.2506-2519, 1999.
DOI : 10.1200/JCO.1999.17.8.2506

D. Ernst, I. Tannock, and E. Winquist, Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain, Journal of Clinical Oncology, vol.21, issue.17, pp.3335-3377, 2003.
DOI : 10.1200/JCO.2003.03.042

J. Bono, . De, C. Logothetis, and A. Molina, Abiraterone and Increased Survival in Metastatic Prostate Cancer, N Engl J Med, vol.364, issue.21, 1995.

C. Ryan, M. Smith, and J. De-bono, Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy, New England Journal of Medicine, vol.368, issue.2, pp.138-186, 2013.
DOI : 10.1056/NEJMoa1209096

H. Scher, K. Fizazi, and F. Saad, Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, New England Journal of Medicine, vol.367, issue.13, pp.1187-97, 2012.
DOI : 10.1056/NEJMoa1207506

T. Beer, A. Armstrong, and D. Rathkopf, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014.
DOI : 10.1056/NEJMoa1405095

K. Fizazi, M. Carducci, and M. Smith, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, The Lancet, vol.377, issue.9768, pp.813-835, 2011.
DOI : 10.1016/S0140-6736(10)62344-6

P. Kantoff, C. Higano, and N. Shore, Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, New England Journal of Medicine, vol.363, issue.5, pp.411-433, 2010.
DOI : 10.1056/NEJMoa1001294

J. De-bono, S. Oudard, and M. Ozguroglu, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, The Lancet, vol.376, issue.9747, pp.1147-54, 2010.
DOI : 10.1016/S0140-6736(10)61389-X

C. Parker, S. Nilsson, and D. Heinrich, Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013.
DOI : 10.1056/NEJMoa1213755

E. Small and C. Ryan, The Case for Secondary Hormonal Therapies in the Chemotherapy Age, The Journal of Urology, vol.176, issue.6, pp.66-71, 2006.
DOI : 10.1016/j.juro.2006.06.071

D. Robinson, E. Van-allen, and Y. Wu, Integrative Clinical Genomics of Advanced Prostate Cancer, Cell, vol.161, issue.5, pp.1215-1243, 2015.
DOI : 10.1016/j.cell.2015.05.001

C. Chen, D. Welsbie, and C. Tran, Molecular determinants of resistance to antiandrogen therapy, Nature Medicine, vol.269, issue.1, pp.33-42, 2004.
DOI : 10.1073/pnas.081565498

H. Scher and C. Sawyers, Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis, Journal of Clinical Oncology, vol.23, issue.32, pp.8253-61, 2005.
DOI : 10.1200/JCO.2005.03.4777

M. Taplin and S. Balk, Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence, Journal of Cellular Biochemistry, vol.259, issue.3, pp.483-90, 2004.
DOI : 10.1177/39.7.1865110

C. Grasso, Y. Wu, and D. Robinson, The mutational landscape of lethal castration-resistant prostate cancer, Nature, vol.10, issue.7406, pp.239-282, 2012.
DOI : 10.1023/A:1018399711996

T. Network, The molecular taxonomy of primary prostate cancer, Cell, vol.163, issue.4, p.1011, 2015.

Y. Ho and S. Dehm, Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer, Endocrinology, vol.26, issue.9, pp.1533-1575, 2017.
DOI : 10.1093/annonc/mdv282

W. Kelly, S. Slovin, and H. Scher, STEROID HORMONE WITHDRAWAL SYNDROMES, Urologic Clinics of North America, vol.24, issue.2, pp.421-452, 1997.
DOI : 10.1016/S0094-0143(05)70389-X

M. Linja, K. Savinainen, O. Saramäki, T. Tammela, R. Vessella et al., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer, Cancer Res, vol.61, issue.9, pp.3550-3555, 2001.

C. Palmberg, P. Koivisto, L. Kakkola, T. Tammela, O. Kallioniemi et al., ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER, The Journal of Urology, vol.164, issue.6, pp.1992-1997, 2000.
DOI : 10.1016/S0022-5347(05)66935-2

J. Veldscholte, C. Ris-stalpers, and G. Kuiper, A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgens, Biochemical and Biophysical Research Communications, vol.173, issue.2, pp.534-574, 1990.
DOI : 10.1016/S0006-291X(05)80067-1

M. Taplin, B. Rajeshkumar, and S. Halabi, Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663, Journal of Clinical Oncology, vol.21, issue.14, pp.2673-2681, 2003.
DOI : 10.1200/JCO.2003.11.102

C. Berrevoets, P. Doesburg, K. Steketee, J. Trapman, and A. Brinkmann, Functional Interactions of the AF-2 Activation Domain Core Region of the Human Androgen Receptor with the Amino-Terminal Domain and with the Transcriptional Coactivator TIF2 (Transcriptional Intermediary Factor 2), Molecular Endocrinology, vol.12, issue.8, pp.1172-83, 1998.
DOI : 10.1210/mend.12.8.0153

W. Tilley, G. Buchanan, T. Hickey, and J. Bentel, Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence, Clin Cancer Res Off J Am Assoc Cancer Res, vol.2, issue.2, pp.277-85, 1996.

J. Edwards and J. Bartlett, The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways, BJU International, vol.59, issue.9, pp.1327-1362, 2005.
DOI : 10.1677/erc.0.0100389

D. Vanaja, S. Mitchell, D. Toft, and C. Young, Effect of geldanamycin on androgen receptor function and stability, Cell Stress & Chaperones, vol.140, issue.1, pp.55-64, 2002.
DOI : 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2

A. Zoubeidi, A. Zardan, and E. Beraldi, Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity, Cancer Research, vol.67, issue.21, pp.10455-65, 2007.
DOI : 10.1158/0008-5472.CAN-07-2057

URL : http://cancerres.aacrjournals.org/content/canres/67/21/10455.full.pdf

C. Paul, F. Manero, S. Gonin, C. Kretz-remy, S. Virot et al., Hsp27 as a Negative Regulator of Cytochrome c Release, Molecular and Cellular Biology, vol.22, issue.3, pp.816-850, 2002.
DOI : 10.1128/MCB.22.3.816-834.2002

URL : https://hal.archives-ouvertes.fr/hal-00194324

C. Concannon, S. Orrenius, and A. Samali, Hsp27 Inhibits Cytochrome <I>c</I>-Mediated Caspase Activation by Sequestering Both Pro-caspase-3 and Cytochrome <I>c</I>, Gene Expression, vol.9, issue.4, pp.4-5195, 2001.
DOI : 10.3727/000000001783992605

A. Parcellier, E. Schmitt, and S. Gurbuxani, HSP27 Is a Ubiquitin-Binding Protein Involved in I-??B?? Proteasomal Degradation, Molecular and Cellular Biology, vol.23, issue.16, pp.5790-802, 2003.
DOI : 10.1128/MCB.23.16.5790-5802.2003

D. Chauhan, G. Li, and K. Podar, The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance, Blood, vol.103, issue.8, pp.3158-66, 2004.
DOI : 10.1182/blood-2003-08-2873

M. Rane, Y. Pan, and S. Singh, Heat Shock Protein 27 Controls Apoptosis by Regulating Akt Activation, Journal of Biological Chemistry, vol.10, issue.30, pp.27828-27863, 2003.
DOI : 10.1128/MCB.22.17.6247-6260.2002

M. Rane, P. Coxon, and D. Powell, p38 Kinase-dependent MAPKAPK-2 Activation Functions as 3-Phosphoinositide-dependent Kinase-2 for Akt in Human Neutrophils, Journal of Biological Chemistry, vol.64, issue.5, pp.3517-3540, 2001.
DOI : 10.1016/0092-8674(94)90277-1

P. Rocchi, A. So, and S. Kojima, Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer, Cancer Research, vol.64, issue.18, pp.6595-602, 2004.
DOI : 10.1158/0008-5472.CAN-03-3998

P. Rocchi, E. Beraldi, and S. Ettinger, Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3???Mediated Suppression of Apoptosis, Cancer Research, vol.65, issue.23, pp.11083-93, 2005.
DOI : 10.1158/0008-5472.CAN-05-1840

P. Cornford, A. Dodson, and K. Parsons, Heat shock protein expression independently predicts clinical outcome in prostate cancer, Cancer Res, vol.60, issue.24, pp.7099-105, 2000.

R. Whelan and B. Hill, Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation, Breast Cancer Research and Treatment, vol.81, issue.1, pp.23-39, 1993.
DOI : 10.1038/bjc.1989.372

E. Richards, E. Hickey, L. Weber, and J. Master, Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells, Cancer Res, vol.56, issue.10, pp.2446-51, 1996.

T. Yamamoto and M. Horikoshi, Novel Substrate Specificity of the Histone Acetyltransferase Activity of HIV-1-Tat Interactive Protein Tip60, Journal of Biological Chemistry, vol.15, issue.49, pp.30595-30603, 1997.
DOI : 10.1101/gad.11.13.1640

T. Ikura, V. Ogryzko, and M. Grigoriev, Involvement of the TIP60 Histone Acetylase Complex in DNA Repair and Apoptosis, Cell, vol.102, issue.4, pp.463-73, 2000.
DOI : 10.1016/S0092-8674(00)00051-9

M. Brady, D. Ozanne, and L. Gaughan, Tip60 Is a Nuclear Hormone Receptor Coactivator, Journal of Biological Chemistry, vol.52, issue.25, pp.17599-604, 1999.
DOI : 10.1210/me.6.5.753

URL : http://www.jbc.org/content/274/25/17599.full.pdf

K. Halkidou, V. Gnanapragasam, and P. Mehta, Expression of Tip60, an androgen receptor coactivator and its role in prostate cancer development, Oncogene, vol.22, issue.16, pp.2466-77, 2003.
DOI : 10.1093/emboj/16.6.1401

M. Shiota, A. Yokomizo, and D. Masubuchi, Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus, The Prostate, vol.283, issue.5, pp.540-54, 2010.
DOI : 10.1128/MCB.19.12.8383

S. Baron, M. Manin, and C. Beaudoin, Androgen Receptor Mediates Non-genomic Activation of Phosphatidylinositol 3-OH Kinase in Androgen-sensitive Epithelial Cells, Journal of Biological Chemistry, vol.21, issue.15, pp.14579-86, 2004.
DOI : 10.1016/0022-4731(89)90098-8

M. Sun, L. Yang, and R. Feldman, Activation of Phosphatidylinositol 3-Kinase/Akt Pathway by Androgen through Interaction of p85??, Androgen Receptor, and Src, Journal of Biological Chemistry, vol.60, issue.44, pp.42992-3000, 2003.
DOI : 10.1038/370527a0

J. Holzbeierlein, P. Lal, and E. Latulippe, Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance, The American Journal of Pathology, vol.164, issue.1, pp.217-244, 2004.
DOI : 10.1016/S0002-9440(10)63112-4

R. Montgomery, E. Mostaghel, and R. Vessella, Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth, Cancer Research, vol.68, issue.11, pp.4447-54, 2008.
DOI : 10.1158/0008-5472.CAN-08-0249

C. Gregory, R. Johnson, J. Mohler, F. French, and E. Wilson, Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen, Cancer Res, vol.61, issue.7, pp.2892-2900, 2001.

E. Koh, T. Noda, J. Kanaya, and M. Namiki, Differential expression of 17?-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues, The Prostate, vol.23, issue.2, pp.154-163, 2002.
DOI : 10.1016/S0022-4731(85)80024-8

K. Fung, E. Samara, and C. Wong, Increased expression of type 2 3??-hydroxysteroid dehydrogenase/type 5 17??-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma, Endocrine Related Cancer, vol.13, issue.1, pp.169-80, 2006.
DOI : 10.1677/erc.1.01048

M. Stanbrough, G. Bubley, and K. Ross, Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer, Cancer Research, vol.66, issue.5, pp.2815-2840, 2006.
DOI : 10.1158/0008-5472.CAN-05-4000

Q. Ji, L. Chang, F. Stanczyk, M. Ookhtens, A. Sherrod et al., Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling, Cancer Research, vol.67, issue.3, pp.1361-1370, 2007.
DOI : 10.1158/0008-5472.CAN-06-1593

H. Klein, M. Bressel, H. Kastendieck, and K. Voigt, Androgens, Adrenal Androgen Precursors, and Their Metabolism in Untreated Primary Tumors and Lymph Node Metastases of Human Prostatic Cancer, American Journal of Clinical Oncology, vol.11, issue.2, pp.30-36, 1988.
DOI : 10.1097/00000421-198801102-00008

M. Titus, C. Gregory, O. Ford, M. Schell, S. Maygarden et al., Steroid 5??-Reductase Isozymes I and II in Recurrent Prostate Cancer, Clinical Cancer Research, vol.11, issue.12, pp.4365-71, 2005.
DOI : 10.1158/1078-0432.CCR-04-0738

J. Luo, T. Dunn, C. Ewing, P. Walsh, and W. Isaacs, Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma, The Prostate, vol.51, issue.2, pp.134-143, 2003.
DOI : 10.1016/S0090-4295(98)00058-2

L. Thomas, R. Douglas, and C. Lazier, Levels of 5??-Reductase Type 1 and Type 2 are Increased in Localized High Grade Compared to Low Grade Prostate Cancer, The Journal of Urology, vol.179, issue.1, pp.147-51, 2008.
DOI : 10.1016/j.juro.2007.08.155

K. Chang, R. Li, and B. Kuri, A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer, Cell, vol.154, issue.5, pp.1074-84, 2013.
DOI : 10.1016/j.cell.2013.07.029

J. Simard, M. Ricketts, S. Gingras, P. Soucy, F. Feltus et al., Isomerase Gene Family, Endocrine Reviews, vol.26, issue.4, pp.525-82, 2005.
DOI : 10.1210/er.2002-0050

R. Auchus, The backdoor pathway to dihydrotestosterone, Trends in Endocrinology & Metabolism, vol.15, issue.9, pp.432-440, 2004.
DOI : 10.1016/j.tem.2004.09.004

E. Mostaghel, B. Montgomery, and P. Nelson, Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease, Urologic Oncology: Seminars and Original Investigations, vol.27, issue.3, pp.251-258, 2009.
DOI : 10.1016/j.urolonc.2009.03.016

T. Nishiyama, Y. Hashimoto, and K. Takahashi, The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer, Clinical Cancer Research, vol.10, issue.21, pp.7121-7127, 2004.
DOI : 10.1158/1078-0432.CCR-04-0913

G. Attard, A. Reid, and T. Yap, Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven, Journal of Clinical Oncology, vol.26, issue.28, pp.4563-71, 2008.
DOI : 10.1200/JCO.2007.15.9749

Z. Li, A. Bishop, and M. Alyamani, Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer, Nature, vol.56, issue.7560, p.347, 2015.
DOI : 10.1373/clinchem.2010.143222

G. Attard, T. Yap, and A. Reid, Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor, J Clin Oncol, vol.25, issue.90180, pp.5063-5063, 2007.

G. Attard, A. Reid, and R. Auchus, Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.2, pp.507-523, 2012.
DOI : 10.1210/jc.2011-2189

G. Attard, A. Reid, A. Hern, and R. , Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer, Journal of Clinical Oncology, vol.27, issue.23, pp.3742-3750, 2009.
DOI : 10.1200/JCO.2008.20.0642

J. Richards, A. Lim, and C. Hay, Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100, Cancer Research, vol.72, issue.9, p.2176, 2012.
DOI : 10.1158/0008-5472.CAN-11-3980

K. Fizazi, R. Jones, and S. Oudard, Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5, Journal of Clinical Oncology, vol.33, issue.7, p.723, 2015.
DOI : 10.1200/JCO.2014.56.5119

C. Tran, S. Ouk, and N. Clegg, Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer, Science, vol.277, issue.29, pp.787-90, 2009.
DOI : 10.1074/jbc.M203310200

M. Hodgson, I. Astapova, and S. Cheng, The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists, Journal of Biological Chemistry, vol.19, issue.8, pp.6511-6520, 2005.
DOI : 10.1210/me.2003-0421

S. Baek, K. Ohgi, and C. Nelson, Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells, Proceedings of the National Academy of Sciences, vol.102, issue.6, pp.3100-3105, 2006.
DOI : 10.1016/S0092-8674(00)00064-7

J. Rosenberg, V. Weinberg, and W. Kelly, Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients, Cancer, vol.106, issue.3, pp.556-63, 2007.
DOI : 10.7164/antibiotics.49.560

I. Tannock, D. Osoba, and M. Stockler, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points., Journal of Clinical Oncology, vol.14, issue.6, pp.1756-64, 1996.
DOI : 10.1200/JCO.1996.14.6.1756

A. Aller, L. Kraus, and M. Bissery, In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines, In: Proc Am Assoc Cancer Res, p.303, 2000.

M. Bissery, H. Bouchard, and J. Riou, Preclinical evaluation of TXD258, a new taxoid, Proc Am Assoc Cancer Res, p.214, 2000.

A. Mita, L. Denis, and E. Rowinsky, Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.15, issue.2, pp.723-753, 2009.
DOI : 10.1158/1078-0432.CCR-08-0596

X. Pivot, P. Koralewski, and J. Hidalgo, A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients, Annals of Oncology, vol.7, issue.7, pp.1547-52, 2008.
DOI : 10.1200/JCO.2006.08.9102

URL : https://hal.archives-ouvertes.fr/inserm-00483407

K. Schulman and J. Kohles, Economic burden of metastatic bone disease in the U.S., Cancer, vol.8, issue.11, pp.2334-2376, 2007.
DOI : 10.3310/hta8040

M. Roudier, C. Morrissey, L. True, C. Higano, R. Vessella et al., Histopathological Assessment of Prostate Cancer Bone Osteoblastic Metastases, The Journal of Urology, vol.180, issue.3, pp.1154-60, 2008.
DOI : 10.1016/j.juro.2008.04.140

J. Brown, R. Cook, and P. Major, Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors, JNCI Journal of the National Cancer Institute, vol.17, issue.4, pp.59-69, 2005.
DOI : 10.1200/JCO.2003.05.147

L. Demers, Bone markers in the management of patients with skeletal metastases, Cancer, vol.14, issue.S3, pp.874-883, 2003.
DOI : 10.1038/16852

R. Percival, G. Urwin, and S. Harris, Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol, vol.13, issue.1, pp.41-50, 1987.

G. Roodman, Mechanisms of Bone Metastasis, New England Journal of Medicine, vol.350, issue.16, pp.1655-64, 2004.
DOI : 10.1056/NEJMra030831

K. Fizazi, J. Yang, and S. Peleg, Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.7, pp.2587-97, 2003.

K. Fizazi, A. Lipton, and X. Mariette, Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates, Journal of Clinical Oncology, vol.27, issue.10, pp.1564-71, 2009.
DOI : 10.1200/JCO.2008.19.2146

J. Locke, E. Guns, and A. Lubik, Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer, Cancer Research, vol.68, issue.15, pp.6407-6422, 2008.
DOI : 10.1158/0008-5472.CAN-07-5997

H. Scher, S. Halabi, and I. Tannock, Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, Journal of Clinical Oncology, vol.26, issue.7, pp.1148-59, 2008.
DOI : 10.1200/JCO.2007.12.4487

K. Fizazi, H. Scher, and A. Molina, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.13, issue.10, pp.983-92, 2012.
DOI : 10.1016/S1470-2045(12)70379-0

N. Engel-nitz, B. Alemayehu, D. Parry, and F. Nathan, Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population, Cancer Manag Res, vol.3, pp.233-278, 2011.

V. Harris, K. Lloyd, S. Forsey, P. Rogers, M. Roche et al., A Population-based Study of Prostate Cancer Chemotherapy, Clinical Oncology, vol.23, issue.10, pp.706-714, 2011.
DOI : 10.1016/j.clon.2011.04.014

E. Small and N. Vogelzang, Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm., Journal of Clinical Oncology, vol.15, issue.1, pp.382-390, 1997.
DOI : 10.1200/JCO.1997.15.1.382

C. Ryan, M. Smith, and K. Fizazi, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.16, issue.2, pp.152-60, 2015.
DOI : 10.1016/S1470-2045(14)71205-7

C. Sweeney, Y. Chen, and M. Carducci, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, New England Journal of Medicine, vol.373, issue.8, pp.737-783, 2015.
DOI : 10.1056/NEJMoa1503747

S. Oudard, K. Fizazi, and L. Sengeløv, Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial???FIRSTANA, Journal of Clinical Oncology, vol.35, issue.28, 2017.
DOI : 10.1200/JCO.2016.72.1068

N. James, M. Sydes, and N. Clarke, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, The Lancet, vol.387, issue.10024, pp.1163-77, 2016.
DOI : 10.1016/S0140-6736(15)01037-5

C. Vale, S. Burdett, and L. Rydzewska, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, The Lancet Oncology, vol.17, issue.2, pp.243-56, 2016.
DOI : 10.1016/S1470-2045(15)00489-1

K. Fizazi, N. Tran, and L. Fein, Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, New England Journal of Medicine, vol.377, issue.4, pp.352-60, 2017.
DOI : 10.1056/NEJMoa1704174

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 1990.
DOI : 10.1016/j.ejca.2008.10.026

P. Therasse, S. Arbuck, and E. Eisenhauer, New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-221, 2000.
DOI : 10.1093/jnci/91.6.523

M. Oken, R. Creech, and D. Tormey, Toxicity and response criteria of the Eastern Cooperative Oncology Group, AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol.5, issue.6, pp.649-55, 1982.
DOI : 10.1097/00000421-198212000-00014

C. Ryan, S. Shah, and E. Efstathiou, Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response, Clinical Cancer Research, vol.17, issue.14, pp.4854-61, 2011.
DOI : 10.1158/1078-0432.CCR-11-0815

K. Fizazi, C. Jenkins, and I. Tannock, Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra, Annals of Oncology, vol.57, issue.(2), pp.1660-1667, 2015.
DOI : 10.1016/j.ejca.2013.11.034

D. Poon, K. Chan, and S. Lee, Abiraterone acetate in metastatic castration-resistant prostate cancer ??? the unanticipated real-world clinical experience, BMC Urology, vol.50, issue.9, p.12, 2016.
DOI : 10.1016/j.ejca.2014.03.010

J. Svensson, E. Andersson, U. Persson, T. Edekling, A. Ovanfors et al., Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden, Scandinavian Journal of Urology, vol.50, issue.4, pp.286-91, 2016.
DOI : 10.1056/NEJMoa1207506